Skip to main content
Caplight Logo









Pharmability AB

Pharmability AB

Private
StockholmHealthcare & Life Scienceshttps://pharmability.com/

Last Round

Early Funding

Apr 9, 2025

Total Funding Raised

$5.66M

Company Overview

Pharmability AB is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis.

Sector

Healthcare & Life Sciences

Verticals

Compliance & Risk, Quality Management, Biotechnology, Medical Devices, RegTech

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

regulatory affairspharmacovigilancequality assuranceGxP compliancepharma consultingsafety monitoringmarket authorizationregulatory complianceinterim managementpharma regulatorylife sciences consultingdrug development supportpost-market surveillanceregulatory servicescompliance outsourcing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pharmability AB Comparables

Compare Pharmability AB with similar companies based on industry and business-model similarity.

Pharmability AB comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
RegSmart Life Science AB
87%
Cencora
77%
LINK Medical
72%

Pharmability AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 9, 2025
GrantAug 1, 2024
Early FundingNov 20, 2020

Key People

Founding team and executive leadership

Leo Holmgren

CEO, Strategic Advisor, Board Member

Executive Team

Pharmability AB Investors

Notable investors and investment history

Pharmability AB investors
InvestorRounds
Almi Invest ABEarly Funding
VinnovaGrant
ScietyEarly Funding
SwelifeGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 18, 2025

    Partnered with Bachem Americas, Inc. for atopic dermatitis therapy.

  • Nov 6, 2025

    Strengthening collaboration with Zelmic AB.

Pharmability AB Filings

Explore SEC and related filing metadata, where available.

Pharmability AB filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Pharmability AB's valuation, stock price, and market status.

Is TIRmed Pharma a public or private company?

TIRmed Pharma is a private company.

What is the current stock price of TIRmed Pharma?

TIRmed Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is TIRmed Pharma worth (valuation)?

Valuation information for TIRmed Pharma is not publicly available.

Can I buy TIRmed Pharma stock?

TIRmed Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was TIRmed Pharma's last funding round?

TIRmed Pharma's most recent funding round was Series A on April 9, 2025.

Who are the main investors in TIRmed Pharma?

Key investors in TIRmed Pharma include Sciety.

Will TIRmed Pharma IPO soon?

No public IPO plans have been announced for TIRmed Pharma.

How can I track TIRmed Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TIRmed Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStockholm
Employee Range1
Year Founded2018
Last FundingApr 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?